Heart failure (HF) represents a growing health issue with significant morbidity, expense, and mortality in western world. Despitea similar prevalence between gender our knowledge about this disease mostly come from studies perfomed in men. Instead, untilnow women have been under-represented in HF trials and this limits our knowledge of HF in women to extrapolation of findings frommen. However according to the available data women with HF differ from men regarding pathophysiology, clinical presentation andprognosis. Women with HF often present at an older age, have a better systolic function, suffer from more comorbidities, have an higherrate of hospital admissions and have a better age-adjusted survival compared to men. Moreover pharmacodynamic specificities related togender have been described. Taken together these gender-related differences can affect response to several kinds of treatments and thegeneral clinical approach to the patient by the physician. The understanding of these differences may improve the clinicalmanagement ofHF and possible new gender-specific diagnostic and therapeutic options may be developed. To this aim, it remains mandatory. to increasethe number of female patients with HF enrolled in clinical trials.
|Number of pages||9|
|Journal||Current Pharmaceutical Design|
|Publication status||Published - 2011|
- Heart failure
ASJC Scopus subject areas
- Drug Discovery